研究瘤亡因子受体在炎症性肠道疾病的研究
Roberta Figueiroa Souza1, Marcos Antônio Ferreira Caetano1, Henrique Inhauser Riceti Magalhães2
1Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
World journal of gastroenterology
|June 5, 2023
概括
瘤亡因子-α (TNF-α) 是炎症性肠病 (IBD) 的关键调解者. 抗TNF-α生物药物通过中和这种细胞因子来有效治疗UC和CD,在许多患者中诱导缓解.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 性结肠炎 (UC) 和克罗恩病 (CD) 是炎症性肠病 (IBD),其特点是炎症和潜在的肠死.
- 瘤坏死因子-α (TNF-α) 是一种关键的促炎性细胞因子,与IBD病原发生有关,在患者的血清中发现了高水平.
- TNF-α与其受体TNFR1和TNFR2相互作用,这些受体在IBD中被检测到并与疾病活性相关.
研究的目的:
- 审查TNF-α在IBD病原发生中的作用.
- 讨论抗TNF-α生物制剂在治疗IBD中的机制和疗效.
- 要突出抗TNF-α疗法的复杂功能,而不仅仅是简单的细胞因子阻断.
主要方法:
- 对TNF-α,其受体和IBD中的抗TNF-α疗法研究的文献综述.
- 分析涉及TNF-α和互白蛋白 (IL-1β,IL-6) 的细胞因子信号通路.
- 对抗TNF-α生物药物在诱导和维持IBD缓解方面的疗效的临床数据的检查.
主要成果:
- TNF-α是IBD的中心调解者,促进炎症和细胞因子的产生.
- 抗TNF-α生物药物彻底改变了IBD治疗方法,在高达60%的患者中实现了临床反应.
- 这些疗法诱导长期缓解,并表现出超出直接TNF-α中和的复杂免疫调节效应.
结论:
- TNF-α在UC和CD的炎症过程中发挥着关键作用.
- 抗TNF-α生物药物代表了IBD管理的重大进步,提供了显著的临床益处.
- 对抗TNF-α抗体的多方面机制的进一步研究可能会揭示IBD的其他治疗策略.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Inflammatory Bowel Disease II: Crohn's Disease
303
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
303
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
364
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
364
Inflammatory Bowel Disease I: Ulcerative Colitis
227
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
227
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Inflammatory Bowel Disease IV: Pharmacological Management
159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
159


